Skip to main content
Equibles
BAX logo

BAX · Baxter International Inc · Metrics

Track BAX — free

Use BAX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BAX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.30 -0.35 (-1.36%) At close · Oct 23
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$13.14B
Shares
517.00M
Volume · Oct 23 4.94M Avg daily vol (3M) 6.64M

BAX metrics

99 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$25.30
Market cap
$13.14B

Price action

20 metrics
Price change (1W)
+0.1%
Price change (30D)
+7.7%
Price change (3M)
+12.9%
Price change (6M)
+39.3%
Price change (YTD)
+32.4%
Price change (1Y)
+10.0%
Trailing year
Price change (5Y)
-69.2%
52-week high
$28.35
52-week low
$15.80
Change from 52-week high
-10.8%
Change from 52-week low
+60.1%
Annualized volatility
43.3%
Annualized volatility (3M)
36.4%
Beta
1.2
RSI (14D)
56.8
Price vs SMA 50
+2.1%
Price vs SMA 200
+19.1%
Avg volume (3M)
6.64M
Relative volume
0.7
Average dollar volume
$167.14M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
517.00M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.8×
reciprocal yield 55.5%
EV / EBITDA
30.4×
reciprocal yield 3.3%
EV / EBIT
—
P / sales
1.1×
reciprocal yield 87.3%
P / book
2.1
reciprocal yield 47.2%
FCF yield
—
TTM · current market cap
Buyback yield
0.2%
P / FCF
—
P / operating cash flow
10.0
reciprocal yield 10.0%
Earnings yield
-8.1%

Historical valuation

8 metrics
P / E historical average (3Y)
37.0×
reciprocal yield 2.7%
P / E historical average (5Y)
38.9×
reciprocal yield 2.6%
EV / revenue historical average (3Y)
2.0×
reciprocal yield 49.9%
EV / revenue historical average (5Y)
2.5×
reciprocal yield 40.7%
EV / EBIT historical average (3Y)
301.0×
reciprocal yield 0.3%
EV / EBIT historical average (5Y)
171.3×
reciprocal yield 0.6%
EV / EBITDA historical average (3Y)
22.1×
reciprocal yield 4.5%
EV / EBITDA historical average (5Y)
21.0×
reciprocal yield 4.8%

Dividends & buybacks

7 metrics
Dividend yield
0.2%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$0.04
Dividend growth YoY
-94.1%
Dividend growth streak
0
Last ex-dividend
2026-08-28

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
30.1%
Operating margin
-2.4%
Trailing 12 months
Net margin
-9.3%
Gross profit (TTM)
$3.45B
Operating profit (TTM)
−$274.00M
Net income (TTM)
−$1.06B
Trailing 12 months
Diluted EPS (TTM)
$-2.09
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$22.31
Gross profit per diluted share (TTM)
$6.70
Operating profit per diluted share (TTM)
$-0.55
EBITDA per diluted share (TTM)
$1.31
Net income per diluted share (TTM)
$-2.09
Operating cash flow per diluted share (TTM)
$2.57
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.00
Stock compensation per diluted share (TTM)
$0.22
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+5.3%
Year over year
Net income growth YoY
+38.5%
Revenue (TTM)
$11.47B
Trailing 12 months
EPS growth YoY
+33.3%
Shares change YoY
+0.8%
Year over year · more shares
Revenue CAGR (3Y)
+3.8%
Revenue CAGR (5Y)
-0.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-26.4%
FCF CAGR (5Y)
-22.1%

Quality

14 metrics
Return on equity
-17.1%
Return on assets
-5.4%
Debt / equity
1.5
Current ratio
1.9
EBITDA (TTM)
$679.00M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
-0.9
Net debt / EBITDA
11.1
Return on invested capital
—
Trailing 12 months
Net cash
−$7.51B
Latest balance sheet
Cash & equivalents
$2.15B
Total assets
$19.79B
Total debt
$9.48B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.32B
Capital expenditures (TTM)
—
R&D (TTM)
$512.00M
SG&A (TTM)
$2.93B
Stock compensation (TTM)
$115.00M
R&D / revenue
4.5%
Stock compensation / revenue
1.0%

Ownership (13F)

9 metrics
13F filers
700
13F filer change QoQ
+28
Institutional ownership
108.9%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.9%
Holder tenure
14.6
Price vs estimated holder cost
-27.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.6%

Short interest

3 metrics
Short interest
4.7%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 10456 CUSIP 071813109 13F (30d) 182 filings 160 filers Visit website Investor relations